$BIIB Launches on aducanumab Approval
BIIB blasted through long-term resistance on the huge news of the company's approval for a first-of-its-kind Alzheimer's treatment. This is a multi-billion-dollar market with effectively no competition.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.